Myriad Genetics

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Myriad Genetics reports robust Q4 growth and eyes market expansion

Myriad Genetics showcased strong revenue growth and strategic initiatives to drive profitability in Q4 2022.
The company's focus on customer engagement, product volumes, and market positioning reflects a commitment to growth and operational excellence.
Challenges in managing competition and optimizing operational efficiency are balanced by opportunities for revenue growth and market expansion.

Myriad Genetics reports strong Q1 earnings, eyes profitability in Q4

Myriad Genetics demonstrated robust performance in Q1, leveraging strategic partnerships and operational improvements to drive revenue growth and enhance testing volumes.
While facing challenges like billing issues and seasonality-related declines, the company remains focused on core products, profitability, and growth opportunities.
With a strong financial outlook, emphasis on innovation, and commercial initiatives, Myriad Genetics is well-positioned to capitalize on market opportunities and drive sustainable growth.

Myriad Genetics reports solid Q2 growth and strategic focus

Myriad Genetics showcased strong financial performance, operational efficiencies, and strategic focus on growth and profitability.
While facing challenges like milestone payment concerns and industry competition, the company's strengths in key segments and operational capabilities position them well.
Opportunities in product enhancements, channel expansions, and investor engagement pave the way for continued success and market leadership.

Myriad Genetics reports strong Q3 earnings and raises 2024 guidance

Myriad Genetics reported strong revenue growth and operational improvements, with a focus on key product lines and enhancing customer experience.
The company raised financial guidance for 2023 and introduced revenue guidance for 2024, showcasing confidence in achieving long-term growth targets.
Challenges include regulatory changes, market penetration, and maintaining profitability amidst competitive dynamics, while opportunities lie in sustained growth and revenue optimization.
Overall, Myriad Genetics demonstrated resilience and strategic focus in driving growth, improving margins, and navigating market challenges effectively.

Myriad Genetics reports strong Q4 performance and eyes market expansion

Myriad Genetics delivered a strong Q4 performance with a focus on growth, strategic investments, and operational improvements. The company faces challenges in pricing and reimbursement but sees opportunities in market expansion and new product launches. Overall, Myriad Genetics is optimistic about its future prospects and market positioning.

Myriad Genetics reports robust Q1 performance and eyes growth opportunities

Myriad Genetics delivered a strong quarter with revenue growth and positive EBITDA, focusing on strategic areas like oncology and women's health. The company is optimistic about exceeding guidance but remains cautious. Analysts raised inquiries about various segments and operational decisions, with the company emphasizing profitable growth and maintaining margins.

Myriad Genetics reports strong Q2 performance and raises revenue targets

Myriad Genetics delivered a robust Q2 performance with revenue growth, positive earnings, and strategic wins in payer coverage, setting the stage for continued growth.
The company's focus on efficiency, customer satisfaction, and profitable growth positions it well for future success amidst market challenges and opportunities.
With raised revenue targets, expanded market acceptance, and operational excellence, Myriad Genetics demonstrates resilience and adaptability in a dynamic healthcare landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

With the receipt of the regulatory approval, Myriad Genetics (MYGN) will be taking a major stride forward in its Oncology and Women's Health segment.

Myriad Genetics (MYGN) Files for myChoice CDx Test sPMA

SALT LAKE CITY, Feb.  12, 2020  (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that R. Bryan Riggsbee, president and CEO, is scheduled to present at the SVB Leerink Global Healthcare Conference at 10:30 a.m. EST on February 25, 2020 in New York City.

Myriad Genetics to Present at the SVB Leerink Global Healthcare Conference

SALT LAKE CITY, Feb.  11, 2020  (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and Drug Administration (FDA) for its myChoice® CDx test to help identify women with advanced ovarian cancer who are potential candidates for maintenance therapy with Lynparza® (olaparib) in combination with bevacizumab. Myriad’s filing is based on the positive results from the Phase 3 PAOLA-1 trial of Lynparza that was published online in the New England Journal of Medicine in December 2019. Lynparza is marketed by AstraZeneca (LSE/STO/NYSE: AZN) and Merck, known as MSD outside of the U.S. and Canada.

Myriad Submits sPMA for myChoice® CDx with Lynparza® in First-Line Maintenance Therapy in Advanced Ovarian Cancer

The molecular diagnostics company also delivered an earnings miss, and its stock plunged.

Myriad Genetics CEO Mark Capone Resigns

The molecular diagnostics company's latest quarterly results weren't anywhere close to what Wall Street expected.

Why Myriad Genetics Shares Are Tanking Today

Myriad Genetics (MYGN) reports decline in Hereditary Cancer, GeneSight, Vectra and Prenatal revenues in Q2.

Myriad Genetics (MYGN) Misses Q2 Earnings & Revenue Estimates

Myriad Genetics, Inc. (MYGN) CEO Bryan Riggsbee on Q2 2020 Results - Earnings Call Transcript

Myriad (MYGN) delivered earnings and revenue surprises of -25.81% and -6.76%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics (MYGN) Misses Q2 Earnings and Revenue Estimates

R. Bryan Riggsbee, Chief Financial Officer Appointed Interim President and CEO

Myriad Announces Leadership Transition

SALT LAKE CITY, Jan.  22, 2020  (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and Drug Administration (FDA) for its myChoice® CDx test to help predict outcomes of women with first-line platinum responsive advanced ovarian cancer treated with GSK’s PARP inhibitor Zejula® (niraparib). Myriad’s filing is based on the positive results from the Phase 3 PRIMA trial of Zejula that was published online in the New England Journal of Medicine in September 2019.

Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line Platinum Responsive Advanced Ovarian Cancer

SALT LAKE CITY, Jan.  21, 2020  (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and Drug Administration (FDA) for its BRACAnalysis® CDx test as a companion diagnostic to AstraZeneca’s (LSE/OMX Nordic/NYSE: AZN) and Merck’s PARP inhibitor Lynparza® (olaparib) for men with metastatic castration-resistant prostate cancer. 

Myriad Submits sPMA for BRACAnalysis® CDx as a Companion Diagnostic  for Lynparza® in Metastatic Castration-resistant Prostate Cancer

SALT LAKE CITY, Jan.  14, 2020  (GLOBE NEWSWIRE) --  Myriad Genetics, Inc.  (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that it has named Thomas P. Slavin, M.D., FACMG, DABMD, senior vice president of Medical Affairs at Myriad Oncology effective March 2, 2020. In this role, Dr. Slavin will provide medical and scientific leadership across Myriad's portfolio of molecular and companion diagnostic products and services for oncology. Dr. Slavin will report to Nicole Lambert, president of Myriad Oncology. 

Dr. Thomas P. Slavin Named Senior Vice President of Medical Affairs for Myriad Oncology

The result of this clinical trial is a major stride forward in Myriad Genetics' (MYGN) commitment toward strengthening its portfolio of depressive disorder treatments.

Myriad Genetics' GUIDED Clinical Trial Outcome Encouraging

SALT LAKE CITY, Jan.  06, 2020  (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in molecular diagnostics and precision medicine, announced that a new analysis of the GUIDED1 clinical trial using the 6-item Hamilton Depression Rating Scale (HAM-D6) was published online in   BMC Psychiatry  . The key finding is the HAM-D6 scale identified statistically significant improvements in all three clinical endpoints – remission, response and symptoms – between GeneSight®-guided care and treatment-as-usual at Week 8 (Figure 1).

New Publication Demonstrates GeneSight® Improved All Clinical Outcomes Using HAM-D6 Analysis in Large Prospective GUIDED Study

Myriad Genetics (MYGN) expands the use of BRACAnalysis CDx as a companion diagnostic test for metastatic pancreatic cancer with the receipt of the FDA clearance.

Myriad Genetics' Cancer Companion Diagnostic Test Gets FDA Nod

Shares of Myriad Genetics initially popped Monday after the Food and Drug Administration approved the company's genetic test, dubbed BRACAnalysis CDx, for pancreatic cancer patients.
The post This Genetic-Testing Stock Popped, Then Slipped, On Its FDA Approval appeared first on Investor's Business Daily.

This Genetic-Testing Stock Popped, Then Slipped, On Its FDA Approval

Share of Myriad Genetics Inc. MYGN, -0.30% shot up 8.3% in premarket trading Monday, after the molecular diagnostics company said its BRACAnalysis CDx was approved by the Food and Drug Administration as a companion test to identify patients with metastatic pancreatic cancer, who are candidates for treatment with Lynparza.

Myriad Genetics's stock surges after FDA approval of diagnostic test for pancreatic cancer

SALT LAKE CITY, Dec.  30, 2019  (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx® for use as a companion diagnostic test by healthcare professionals to identify patients with metastatic pancreatic cancer who have a germline BRCA mutation and are candidates for treatment with PARP inhibitor Lynparza ®  (olaparib).  Lynparza is marketed by AstraZeneca (LSE/OMX Nordic/NYSE: AZN) and Merck, known as MSD outside of the U.S. and Canada.  BRACAnalysis CDx is the first and only FDA-approved genetic test for this indication.

Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germline BRCA-mutated Metastatic Pancreatic Cancer

Exact Sciences

Which stock wins in a battle between these two genomic testing leaders?

Better Buy: Exact Sciences vs. Myriad Genetics

SALT LAKE CITY, Dec.  19, 2019  (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and precision medicine, announced that board member S. Louise Phanstiel has been named to WomenInc. Magazine’s 2019 Most Influential Corporate Board Directors list.  The list includes female directors serving on the boards of publicly traded companies and is the most comprehensive directory of women executives, influencers and achievers who contribute to leadership on corporate boards.

Myriad Genetics’ Board Member, S. Louise Phanstiel, Recognized by WomenInc.

Myriad Genetics' (MYGN) PRS enhances the detection of breast cancer risk in women having PV in high- and moderate-penetrance breast cancer genes.

Myriad Genetics Presents Trial Outcomes in Breast Health

New Clinical Validation Study Presented at 2019 San Antonio Breast Cancer Symposium New Clinical Validation Study Presented at 2019 San Antonio Breast Cancer Symposium

Myriad’s Polygenic Risk Score Personalizes Risk of Breast Cancer for Woman with a Genetic Mutation in Important Breast Cancer Genes

Myriad Genetics (MYGN) posts breakthrough results on Prequel Prenatal Screen methodology, proving its superiority over traditional methods.

Myriad Genetics Reports Favorable Study Result on Prequel

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?

Myriad (MYGN) Up 18.4% Since Last Earnings Report: Can It Continue?

Shares of Myriad Genetics  dropped 3% in premarket trading after the diagnostics maker said its Prequel prenatal screening test is better than non-DNA tests at identifying chromosomal abnormalities in pregnant women with a high body mass index. The study's results were published in the journal Prenatal Diagnosis.

News for Myriad Genetics Stock (MYGN)